Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI

Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI

Abstract Background To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we investigated whether a single dose of a monoaminergic drug (methylphenidat...

Full description

Bibliographic Details
Main Authors: Jolien F. Leijenaar, Geert Jan Groeneveld, Erica S. Klaassen, Anna E. Leeuwis, Philip Scheltens, Henry C. Weinstein, Joop M. A. van Gerven, Frederik Barkhof, Wiesje M. van der Flier, Niels D. Prins
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
Vascular cognitive impairment
Methylphenidate
Galantamine
Cognition
Vascular dementia
MCI
Online Access:https://doi.org/10.1186/s13195-019-0567-z

Internet

https://doi.org/10.1186/s13195-019-0567-z

Similar Items